Part II: Liver function in oncology: towards safer chemotherapy use. (Q37336474)

19 August 2017

1 reference

title

Part II: Liver function in oncology: towards safer chemotherapy use. (English)

1 reference

19 August 2017

1 reference

Kathryn M Field

1

1 reference

PubMed ID

19038765

19 August 2017

Michael Michael

series ordinal

2

1 reference

19 August 2017

1 December 2008

1 reference

Lancet Oncology Commission

19 August 2017

1 reference

19 August 2017

9

1 reference

19 August 2017

12

1 reference

19 August 2017

1181-1190

1 reference

Antecedent liver disease and drug toxicity

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Pharmacokinetics of anticancer agents in patients with impaired liver function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Clinical pharmacokinetics of docetaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Predicting etoposide toxicity: relationship to organ function and protein binding

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Pharmacokinetics of vinorelbine in patients with liver metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Five years clinical experience with 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Factors affecting cytochrome P-450 3A activity in cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Dexamethasone as a probe for vinorelbine clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Genetic testing in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Clinical pharmacokinetics of docetaxel : recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Population pharmacokinetics of weekly docetaxel in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Assessing liver function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

How I do it: assessment of hepatic functional reserve for indication of hepatic resection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Model for end-stage liver disease (MELD) and allocation of donor livers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Pharmacogenetics of irinotecan metabolism and transport: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970307-3

7 January 2021

10.1016/S1470-2045(08)70307-3

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

19038765